# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
GIGA-2339 is the first recombinant polyclonal therapeutic in development to treat and functionally cure chronic hepatitis B vir...
https://www.bloomberg.com/news/articles/2024-07-30/grifols-new-auditor-finds-non-cash-accounting-discrepancy-linked-to-china-st...
- Reuters
Grifols reveals Brookfield Capital's preliminary discussions with major shareholders about a potential joint bid to delist ...
GRFS: 31% | Brookfield Confirms It Held Exploratory Discussions With Certain Reference Shareholders Of Co In Relation To A Pote...
In relation to certain rumors appearing in the media about a potential transaction involving Grifols, S.A. ("Grifols" o...